EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDREN

This paper shows the research results of the biological therapy with chimeric monoclonal antibody to tumor necrosis factor (TNF) (infliximab). 33 children aged 6 to 18 years with various forms of Crohn’s disease were enrolled in the study. Therapy duration ranged from 3 months to 1 year or more. Af...

Full description

Saved in:
Bibliographic Details
Main Authors: E. G. Tsimbalova, A. S. Potapov, M. M. Venedictova, F. F. Shavrov
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2012-01-01
Series:Вопросы современной педиатрии
Subjects:
Online Access:https://vsp.spr-journal.ru/jour/article/view/523
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items